Brain Small Chain Fatty Acid Metabolism in Parkinson Disease: Ketones

• Status: Not yet recruiting
• Trial end date: 2025-05-01
• Target enrollment: 0
• Participant gender: All

Summary

Small exploratory open-label pilot study to assess supplementation of a ketone ester (KetoneAid) as a potential therapy for persons with Parkinson disease (PD), Parkinson Disease Dementia/Lewy Body Dementia (PDD/LBD), and healthy controls.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Michigan
• Collaborator: Farmer Family Foundation

Criteria

Inclusion Criteria:

• Healthy control volunteers over 45 years of age

• People with Parkinson Disease over 45 years of age

• People with Parkinson's Disease Dementia or Lewy Body Dementia over 45 years of age

Exclusion Criteria:

• Participants with contra-indications to MR imaging, including pacemakers or claustrophobia;

• Evidence of large vessel stroke or mass lesion on MRI

• Regular use of anti-cholinergic, benzodiazepines, high dose (>100mg QD) of quetiapine, or neuroleptic drugs

• History of significant GI disease

• Significant metabolic or uncontrolled medical comorbidity

• Poorly controlled diabetes

• Pregnancy or breast feeding

• Current excessive alcohol use

• Suicidal ideation